Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03727009|
Recruitment Status : Terminated (COVID-19)
First Posted : November 1, 2018
Last Update Posted : September 25, 2020
|Condition or disease||Intervention/treatment|
|Hematologic Malignancy||Other: Blood Sample Collection|
|Study Type :||Observational|
|Actual Enrollment :||409 participants|
|Official Title:||Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies|
|Actual Study Start Date :||December 7, 2018|
|Actual Primary Completion Date :||March 24, 2020|
|Actual Study Completion Date :||March 24, 2020|
Subjects with clinically confirmed hematologic malignancy and who are treatment naive will provide a blood sample at the time of enrollment. No additional blood draws will occur.
Other: Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
- Blood-based biomarkers associated with genetic and epigenetic alterations. [ Time Frame: Point in time blood collection (1 day) at enrollment ]Biomarkers under evaluation include differential methylation of nucleic acids and altered expression of proteins in blood from subjects with a hematologic malignancy at the pre-intervention stage.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03727009